Who are Experimental: CD07223 1.5% Topical Gel TID's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Meropenem + Fosfomycin, Placebo to Fosfomycin, Fosfomycin and imipenem, Vancocin, Fosfomycin Oral Suspension, Ceftazidime-avibactam + Fosfomycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/experimental-cd07223-1-5-topical-gel-tid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Experimental: CD07223 1.5% Topical Gel TID — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Experimental: CD07223 1.5% Topical Gel TID (Experimental: CD07223 1.5% Topical Gel TID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: betalactamase inhibitor. Area: Infectious Diseases.

phase 2 betalactamase inhibitor MurA Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Experimental: CD07223 1.5% Topical Gel TID (Experimental: CD07223 1.5% Topical Gel TID) — NovaBay Pharmaceuticals, Inc.. CD07223 is an experimental drug that targets the bacterial cell wall synthesis pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Experimental: CD07223 1.5% Topical Gel TID TARGET	Experimental: CD07223 1.5% Topical Gel TID	NovaBay Pharmaceuticals, Inc.	phase 2	betalactamase inhibitor	MurA
Meropenem + Fosfomycin	Meropenem + Fosfomycin	National University of Singapore	marketed	Combination antibiotic (carbapenem + phosphonic acid antibiotic)	Penicillin-binding proteins (meropenem); MurA/UDP-N-acetylglucosamine enolpyruvyl transferase (fosfomycin)
Placebo to Fosfomycin	Placebo to Fosfomycin	University Medical Center Goettingen	marketed	Antibiotic (phosphonic acid derivative)	MurA (UDP-N-acetylglucosamine enolpyruvyl transferase)
Fosfomycin and imipenem	Fosfomycin and imipenem	Juan A. Arnaiz	marketed	Beta-lactam antibiotic combination	Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins)
Vancocin	vancomycin	ANI Pharmaceuticals	marketed		Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase
Fosfomycin Oral Suspension	Fosfomycin Oral Suspension	Public Health Service of Amsterdam	marketed	Cell wall synthesis inhibitor	MurA (enolpyruvate transferase)
Ceftazidime-avibactam + Fosfomycin	Ceftazidime-avibactam + Fosfomycin	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor combination + phosphonic acid antibiotic	Penicillin-binding proteins (PBPs), beta-lactamases, MurA enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-11-06 — Vancocin · 11517609 · Method of Use · US
2035-11-06 — Vancocin · 10188697 · Formulation · US
2035-11-06 — Vancocin · 10039804 · Formulation · US
2035-11-06 — Vancocin · 10849956 · Formulation · US
2035-11-06 — Vancocin · 11000567 · Formulation · US

Sponsor landscape (betalactamase inhibitor class)

NovaBay Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Experimental: CD07223 1.5% Topical Gel TID — Competitive Intelligence Brief. https://druglandscape.com/ci/experimental-cd07223-1-5-topical-gel-tid. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab